KR102344295B1 - 헤테로사이클 유도체 및 이의 용도 - Google Patents

헤테로사이클 유도체 및 이의 용도 Download PDF

Info

Publication number
KR102344295B1
KR102344295B1 KR1020190064284A KR20190064284A KR102344295B1 KR 102344295 B1 KR102344295 B1 KR 102344295B1 KR 1020190064284 A KR1020190064284 A KR 1020190064284A KR 20190064284 A KR20190064284 A KR 20190064284A KR 102344295 B1 KR102344295 B1 KR 102344295B1
Authority
KR
South Korea
Prior art keywords
pyrido
bromo
imidazo
mmol
methylpiperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020190064284A
Other languages
English (en)
Korean (ko)
Other versions
KR20190137013A (ko
Inventor
고광석
권영진
김정숙
윤지훈
이순옥
이지은
조남철
Original Assignee
주식회사 씨앤드씨신약연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 씨앤드씨신약연구소 filed Critical 주식회사 씨앤드씨신약연구소
Publication of KR20190137013A publication Critical patent/KR20190137013A/ko
Application granted granted Critical
Publication of KR102344295B1 publication Critical patent/KR102344295B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020190064284A 2018-05-31 2019-05-31 헤테로사이클 유도체 및 이의 용도 Expired - Fee Related KR102344295B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180062254 2018-05-31
KR1020180062254 2018-05-31

Publications (2)

Publication Number Publication Date
KR20190137013A KR20190137013A (ko) 2019-12-10
KR102344295B1 true KR102344295B1 (ko) 2021-12-29

Family

ID=68698381

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190064284A Expired - Fee Related KR102344295B1 (ko) 2018-05-31 2019-05-31 헤테로사이클 유도체 및 이의 용도

Country Status (12)

Country Link
US (1) US20210198259A1 (https=)
EP (1) EP3807282A4 (https=)
JP (1) JP2021525738A (https=)
KR (1) KR102344295B1 (https=)
CN (1) CN112204032A (https=)
AU (1) AU2019279421A1 (https=)
BR (1) BR112020023946A2 (https=)
CA (1) CA3098825A1 (https=)
MX (1) MX2020011955A (https=)
SG (1) SG11202010985TA (https=)
TW (1) TW202021969A (https=)
WO (1) WO2019231270A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
IL298760A (en) 2020-06-05 2023-02-01 Kinnate Biopharma Inc Fibroblast growth factor receptor kinase inhibitors
EP4067357A1 (en) * 2021-03-30 2022-10-05 JW Pharmaceutical Corporation Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate
CN113929634A (zh) * 2021-11-22 2022-01-14 山西永津集团有限公司 一种2,3-二溴喹喔啉的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112731A2 (en) 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20120015953A1 (en) 2010-07-19 2012-01-19 Clay Beauregard Methods and compositions for the treatment of allergy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE358395B (https=) * 1967-09-27 1973-07-30 Siegfried Ag
BRPI0407926A (pt) * 2003-03-27 2006-02-21 Pfizer Prod Inc 4-amino[1,2,4]triazol[4,3-a]quinoxalinas substituìdas
TW201024297A (en) * 2008-09-10 2010-07-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
TWI551600B (zh) * 2011-09-30 2016-10-01 Ｃ＆Ｃ新藥研究所 新穎雜環衍生物及其用途
CA2904364A1 (en) * 2013-03-15 2014-09-25 Epigenetix, Inc. Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
JP2018537450A (ja) * 2015-11-16 2018-12-20 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ Ｄｎａメチルトランスフェラーゼ阻害剤としての新規化合物
JP7212612B2 (ja) * 2016-07-28 2023-01-25 プロメガ コーポレイション セレンテラジン類縁体

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112731A2 (en) 2010-03-10 2011-09-15 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
US20120015953A1 (en) 2010-07-19 2012-01-19 Clay Beauregard Methods and compositions for the treatment of allergy

Also Published As

Publication number Publication date
US20210198259A1 (en) 2021-07-01
TW202021969A (zh) 2020-06-16
BR112020023946A2 (pt) 2021-02-23
EP3807282A1 (en) 2021-04-21
MX2020011955A (es) 2021-01-15
CN112204032A (zh) 2021-01-08
SG11202010985TA (en) 2020-12-30
CA3098825A1 (en) 2019-12-05
WO2019231270A1 (en) 2019-12-05
EP3807282A4 (en) 2022-03-02
JP2021525738A (ja) 2021-09-27
KR20190137013A (ko) 2019-12-10
AU2019279421A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
US10077243B2 (en) Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
JP6031107B2 (ja) 新規な複素環誘導体及びその用途
KR102344295B1 (ko) 헤테로사이클 유도체 및 이의 용도
JP2023538060A (ja) 二環化合物、それを含む組成物、及びそれらの使用
US10513523B2 (en) Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
JP2019108342A (ja) Ｂｔｋ活性阻害剤としてのヘテロアリールピリドン及びアザピリドン化合物
WO2009067547A1 (en) Polo-like kinase inhibitors
TW202104223A (zh) 磷脂醯肌醇3-激酶抑制劑
BR112012023664B1 (pt) Compostos derivados de 2,3-di-hidro-1hinden-1-il-2,7- diazaspiro [3,5] nonano e composiçãofarmacêutica compreendendo os mesmos
KR20210046714A (ko) 피라진 화합물 및 이의 용도
US12492210B2 (en) Tricyclic compounds and their use
WO2023006013A1 (zh) 新型parp7抑制剂及其应用
US10377770B2 (en) Tricyclic compounds and compositions as kinase inhibitors
JP2021525738A5 (https=)
EP4163283A1 (en) Compound having macrocyclic structure and use thereof
JPWO2019231270A5 (https=)
HK40034987A (en) Heterocyclic derivatives and use thereof
EA047819B1 (ru) Трициклические соединения и их применение
US20240238425A1 (en) HSD17B13 Inhibitors and/or Degraders
HK40077672A (en) Pyridone boronates for the preparation of inhibitors of btk activity
TW202241906A (zh) 吲唑化合物
HK40074528A (en) Heteroaryl pyridone and aza-pyridone compounds as inhibitors of btk activity
HK40060604A (en) Tricyclic compounds and their use

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241224

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241224

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241224